Skip to main
ALLR
ALLR logo

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc. presents an attractive investment opportunity, as indicated by the raising of its 12-month price target based on a net present value (NPV) analysis, which highlights significant upside potential. The company's lead product, stenoparib, demonstrates promising and durable clinical benefits for patients with advanced recurrent ovarian cancer, especially those with limited treatment options available. Additionally, the strategic use of the proprietary Drug Response Predictor technology aims to enhance patient selection and clinical outcomes, further bolstering the company’s growth trajectory in the precision medicine sector.

Bears say

Allarity Therapeutics reported a net loss of $2.37 million, resulting in earnings per share (EPS) of $(0.15), which was better than estimated EPS of $(0.21), indicating ongoing financial challenges. The outlook remains negative due to significant balance sheet and liquidity risks, compounded by the potential failure of the company's product candidates to prove safety and efficacy in clinical trials, as well as regulatory hurdles. Additional concerns include difficulties in commercialization, obtaining reimbursement, competitive pressures, and broader macroeconomic factors impacting the biotech sector.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Dec 13, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.